Evidence map›Paper›PMID 34018147›Full record

Trial reportAdvances in therapy2021

Effects of Combined Lipid-Lowering Therapy on Low-Density Lipoprotein Cholesterol Variability and Cardiovascular Adverse Events in Patients with Acute Coronary Syndrome.

Huilian Tan, Ling Liu, Qinghou Zheng, Dahong Zhang, Qian Liu, Dong Cui, Lei Gao, Zhen Wang, Wen-Lei Wang, Jun Liu

Abstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Advances in therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 6 pooled it
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 6 syntheses or guidelines pooled it, 11 citations in OpenAlex.

  1. A Meta-analysis of the Regulation of Low-Density Lipoprotein Cholesterol and Proprotein Convertase Subtilisin-Kexin Type 9 with Inclisiran.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2025 · on this map
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Article
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Huilian Tan *Department of Cardiology, First Hospital of Hebei Medical University, Shijiazhuang, China.
Ling Liu *Department of Cardiology, First Hospital of Hebei Medical University, Shijiazhuang, China.
Qinghou ZhengDepartment of Cardiology, First Hospital of Hebei Medical University, Shijiazhuang, China.
Dahong ZhangDepartment of Cardiology, First Hospital of Hebei Medical University, Shijiazhuang, China.
Qian LiuDepartment of Cardiology, First Hospital of Hebei Medical University, Shijiazhuang, China.
Dong CuiDepartment of Cardiology, First Hospital of Hebei Medical University, Shijiazhuang, China.
Lei GaoDepartment of Cardiology, First Hospital of Hebei Medical University, Shijiazhuang, China.
Zhen WangDepartment of Cardiology, First Hospital of Hebei Medical University, Shijiazhuang, China.
Wen-Lei WangDepartment of Neurosurgery, Emergency General Hospital, Beijing, China.
Jun LiuDepartment of Cardiology, First Hospital of Hebei Medical University, Shijiazhuang, China. 13582361168@163.com.
Hebei Medical University · CNFirst Affiliated Hospital of Hebei Medical University · CNBeijing Emergency Medical Center · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionTo investigate the effect of combined lipid-lowering therapy on low-density lipoprotein cholesterol (LDL-C) variability and cardiovascular adverse events in patients with acute coronary syndrome (ACS).

methodsA total of 200 patients with acute coronary syndrome, admitted to the first Hospital of Hebei Medical University from January 2018 to June 2019, were randomly divided into the observation group (100 cases were treated with combined lipid-lowering drugs, including 10 mg/day atorvastatin and 10 mg/day ezetimibe) and the control group (100 cases were given an intensive statin regimen, including 40 mg/day atorvastatin). The levels of blood lipids, creatine kinase (CK), alanine transaminase (ALT), matrix metalloproteinase-9 (MMP-9) and high-sensitivity C-reactive protein (hsCRP) were observed and compared between the two groups. Focus was laid on the concentration of the above-mentioned parameters and follow-up results including the drug safety and incidence of cardiovascular adverse events.

resultsBefore treatment, there was no significant difference in total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), CK, ALT, MMP-9, hsCRP and LDL-C between the two groups (P > 0.05). After 6 months, 12 months and 24 months of treatment, TC, HDL-C, CK, ALT, MMP-9, hsCRP and LDL-C were improved in both groups, and TC, HDL-C, CK, ALT, MMP-9, hsCRP and LDL-C in the observation group elicited greater results than those in the control group with significant difference (P < 0.05). In the course of treatment, the drug safety of the two groups was compared (P > 0.05), and the incidence of cardiovascular adverse events in the observation group was significantly lower than that in the control group (6.59% vs. 11.96%) (P < 0.05).

conclusionCombination therapy with atorvastatin and ezetimibe potentially provides remarkable effects in terms of treating acute coronary syndrome, controlling the variation of LDL-C, alleviating the inflammatory state and reducing the incidence of cardiovascular adverse events with a safe profile. Combined lipid-lowering drugs are considered valid and alternative approaches for wide clinical practice.

Indexed as

Acute Coronary SyndromeAnticholesteremic AgentsHydroxymethylglutaryl-CoA Reductase InhibitorsCholesterol, LDLDrug Therapy, CombinationHumansLipidsTreatment OutcomeAnticholesteremic AgentsCholesterol, LDLHydroxymethylglutaryl-CoA Reductase InhibitorsLipidsAcute coronary syndromeAtorvastatinCardiovascular adverse eventsEzetimibeLDL-C variability

Identifiers

PMID34018147
OpenAlexW3162784462

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.